CTOs on the Move

BioBuzz

www.biobuzz.io

 
Biotech and Life Science News, Jobs, and Events for the BioHealth Capital Region - Maryland, D.C., and Virginia. BioBuzz: Be More Connected.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million
  • www.biobuzz.io
  • 1, Helen Heneghan Way
    Rockville, MD USA 20850
  • Phone: 619.916.7620

Executives

Name Title Contact Details

Similar Companies

Arch Oncology

Arch Oncology, Inc. is a clinical-stage immuno-oncology company focused on the discovery and development of potential best-in-class antibody therapies for the treatment of patients with solid tumors and hematologic malignancies.

Element Biosciences

Element Biosciences is a multi-disciplinary startup focused on innovating genetic analysis tools for the research and diagnostic markets. The Company`s technology will broaden the end user experience through improved data quality and simplified workflows to benefit discoveries and diagnosis in healthcare.

Regenxbio

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO`s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO`s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO`s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.

Medrad

MEDRAD, Inc. is a worldwide leading provider of medical devices and services that enable and enhance imaging procedures of the human body. Used in diagnostic imaging, MEDRAD's product offerings include a comprehensive line of vascular injection systems,

Bioporto

BioPorto s flagship product, The NGAL Test™, aids in the risk assessment of AKI in critically ill patients. CE marked for IVD use in select regions.